CCTV Exposure: The price of Chinese medicine has risen again

1

Prices of medicinal materials have generally risen

Recently, the market prices of Chinese medicinal materials have generally risen.

The medicinal material dealers in the Bozhou medicinal material market said that the prices of bulk medicinal materials such as Angelica and Scutellariae are much higher than last year.

However, the prices of medicinal materials are affected by many factors, and it is more difficult to predict the rise or fall.

In fact, in addition to the Bozhou medicinal material market, there are also many varieties of Anguo Medicine that are on the rise.

(Source: Chinese Medicine World Net)

It is understood that the main factors affecting the price of medicinal materials are insufficient inventory, weather and rain, and customs control.

For example, the price of white peony in the Bozhou medicinal material market has risen because the price of white peony has continued to fall in recent years, and the enthusiasm of growers has been significantly reduced.

A CCTV reporter learned from the Bozhou Pharmaceutical Development and Promotion Bureau that according to the local white peony planting area in 2019, its annual output should reach 100,000 tons, but the actual mining output is only 80,000 tons.

In addition, patchouli due to heavy rain last year, and the roots of patchouli were not drained in time, resulting in poor quality of medicinal materials and low yields.

Southeast Asian varieties such as cardamom and black pepper have not yet recovered due to the impact of import and export, and the supply exceeds demand and prices have risen.

2

The impact of the new pharmacopoeia on the industry

In fact, CCTV reported a general increase in the prices of Chinese medicinal materials two months ago.

The new version of the Pharmacopoeia has raised the quality requirements for many varieties, especially the heavy metal content and pesticide residues of drugs, which directly led to the increase in the price of medicinal materials that meet the standards.

The industry believes that the standards of the new pharmacopoeia put forward higher requirements for related companies.

Enterprises should increase their attention to the construction of Chinese medicinal material breeding bases.

The new pharmacopoeia's improvement of the quality standards of Chinese medicines may stimulate the price of Chinese medicinal materials in a short period of time, but in the long run, the implementation of stricter quality standards will undoubtedly regulate the healthier development of the entire Chinese medicinal materials.

It is understood that the current Chinese medicine decoction pieces market has a scale of more than 200 billion yuan, but there are probably more than a thousand Chinese medicine decoction pieces processing companies, and the market share of leading enterprises is not high.

In addition, the publication of higher standards of the new version of the Pharmacopoeia is also conducive to the development of medicinal materials e-commerce.

At present, the development of my country's decoction pieces market is still immature, and high standards will cause a certain degree of change in the market, but after this process, it will be beneficial to the development of the medicinal material market.